Challenges In Valuing The Impact Of Sexually Transmitted Infections

Published Jan 23, 2014
Birmingham, United Kingdom - Sexually transmitted infections like chlamydia are a global public health concern. Chlamydia can cause infertility and other reproductive tract problems in women. Health policy decision makers need to know which interventions they should prioritise to get the best value from the resources available for the prevention and control of sexually transmitted infections. Researchers at the University of Birmingham, with support from a clinical expert at the University of Bern, Switzerland, reviewed studies examining the health impacts of chlamydia infections and their complications. The researchers found that there was a lack of evidence to inform economic evaluations in this area. They suggested that future cost-effectiveness studies need to highlight the lack of primary data available and examine more fully the methodological challenges involved in valuing health states for chlamydia. Tracy Roberts, who designed the study, said: "Researchers and policy makers need to pay more attention to the impact of sexually transmitted infections on health and quality of life. Our study shows major gaps in our knowledge about this important area of human health. Our findings contribute to debates about the methods we should use to value health outcomes. Addressing these issues is crucial to ensuring that policy makers are fully informed when making funding decisions." The full study "Valuing the Health States Associated with Chlamydia trachomatis Infections and Their Sequelae: A Systematic Review of Economic Evaluations and Primary Studies," is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×